United States

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

21 Nov 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide... (more)


Beta: 1.29
Market Cap(Mil.): $65.49
Shares Outstanding(Mil.): 24.25
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 30.23 15.49
EPS (TTM): -- -- --
ROI: -- 8.05 11.95
ROE: -- 11.92 15.94

BRIEF-Cancer Genetics Q3 loss per share $0.15

* Cancer genetics reports record third quarter 2017 revenue and 134% increase in contracted bookings from major biotech and pharmaceutical companies

Nov 09 2017

BRIEF-Cancer Genetics to acquire vivoPharm

* Cancer Genetics announces transformative and accretive acquisition of vivoPharm, a global oncology & immuno-oncology discovery services company

Aug 14 2017

BRIEF-Cancer Genetics reports Q2 loss per share $0.16

* Cancer Genetics Inc announces second quarter 2017 financial results, accretive acquisition and capital raise

Aug 14 2017

BRIEF-DIA elects Cancer Genetics Inc's John A. (Jay) Roberts as Chairman of board

* DIA elects Cancer Genetics Inc's John A(Jay) Roberts as chairman of DIA board of directors

Aug 03 2017

BRIEF-Cancer Genetics files for mixed shelf of up to $100 mln

* Cancer Genetics inc files for mixed shelf of up to $100 million - sec filing Source text for Eikon: Further company coverage:

May 25 2017

Earnings vs. Estimates